Recombinant Mouse Complement component C9 (C9)

What is the molecular structure of mouse C9 and how does it compare to human C9?

Mouse C9 shares structural homology with human C9, belonging to the membrane attack complex/perforin/cholesterol-dependent cytolysin (MACPF/CDC) family. Crystallographic studies have determined the structure of monomeric murine C9 at 2.2 Å resolution, while cryo-electron microscopy has revealed the structure of polymeric C9 assemblies at 3.9 Å resolution . The protein contains distinctive transmembrane regions that undergo conformational changes during MAC assembly. The first transmembrane region (TMH1) of C9 is uniquely positioned in the monomeric form and serves as an inhibitory element that prevents spontaneous polymerization in the absence of the C5b-8 complex .

What is the specific role of C9 in the complement system?

C9 functions as the terminal pore-forming component of the MAC. During complement activation, C9 is the last protein to bind to the assembling MAC, completing the sequence of events that leads to target membrane destruction . While hemolysis can occur without C9, its presence significantly increases the rate of this process . Multiple C9 molecules bind to membrane-associated C5b-8 complexes and polymerize to form the characteristic pore structure of the MAC . This polymerization process follows C9 recruitment to C5b-8, which triggers a conformational change in TMH1, allowing sequential binding of additional C9 monomers to the growing complex .

How does mouse C9 assembly differ from other pore-forming proteins?

The mechanism of C9 assembly in MAC formation contrasts with related pore-forming proteins such as perforin and cholesterol-dependent cytolysins. In these related proteins, a pre-pore assembly occurs first, followed by simultaneous release of transmembrane regions . By contrast, C9 assembly in the MAC occurs through unidirectional and sequential binding of C9 monomers after an initial conformational change triggered by interaction with C5b-8 . This sequential assembly mechanism is critical for proper formation of the MAC pore structure.

How can researchers effectively measure C9-dependent complement activation in mouse models?

Measuring C9-dependent complement activation requires careful consideration of several factors. First, researchers should collect blood samples in tubes containing appropriate anticoagulants that don't activate complement artificially. EDTA is often preferred over heparin, which can activate the complement pathway . For hemolytic assays, antibody-sensitized mouse red blood cells (MRBCs) can be used in conjunction with complement sources (such as human, guinea pig, or rat serum) to test complement-dependent hemolysis in vitro .

For in vivo studies, anti-MRBC antisera can be injected into mice to evaluate antibody-activated complement hemolysis. The extent of hemolysis can be quantified by measuring free hemoglobin in plasma samples collected at specific time points after injection . When comparing C9-sufficient and C9-deficient mice, researchers should note that while C9-deficient mice show attenuated hemolysis, some hemolytic activity still occurs through C5b-8 complexes .

What are the critical considerations when designing experiments to study C9 polymerization?

When studying C9 polymerization, researchers should consider:

• Temperature control: C9-mediated polymerization and hemolysis are temperature-sensitive reactions . Experiments should be conducted at physiologically relevant temperatures (37°C), with appropriate controls at different temperatures to assess kinetic parameters.

• Molar ratios: The C9:C8 ratio is critical as it determines the size of transmembrane channels formed by C5b-9 . Titration experiments with varying C9:C8 ratios should be included to determine optimal polymerization conditions.

• Membrane composition: The lipid composition of target membranes significantly affects C9 polymerization and insertion. When using artificial membranes or cell models, the lipid composition should mimic physiological conditions as closely as possible.

• Visualization techniques: To study the ultrastructure of C9 polymers, high-resolution techniques such as cryo-electron microscopy (3.9 Å resolution has been achieved) and crystallography can be employed . For functional studies, fluorescently labeled C9 can be used to track polymerization in real-time.

• Inhibition studies: Experiments should include controls with specific inhibitors of the transmembrane regions to validate the polymerization mechanism through TMH1 .

What are the known discrepancies in the literature regarding C9 structure and function?

Several notable discrepancies exist in the literature regarding C9 structure and function:

• MAC composition: There are contradicting views on whether the MAC has a monomeric or oligomeric structure. Some studies indicate a dimeric nature of the MAC, supported by molecular weight studies and molecular hybridization experiments, while others suggest a monomeric C5b-9 composition . Some research indicates a tendency of the MAC to form larger MAC oligomers.

• C9 polymerization mechanism: While recent structural studies suggest a sequential recruitment model for C9 assembly , earlier studies proposed alternative mechanisms, including simultaneous insertion of multiple C9 molecules.

• Functional redundancy: The degree to which C9 is essential for MAC function shows some variance across studies. While some research indicates that C9-deficient mice have significantly attenuated complement-dependent hemolysis, other studies show that the C5b-8 complex alone can mediate some level of membrane damage .

• Species differences: There are notable differences in complement activity between species, with rat serum showing lower hemolytic capacity compared to human or guinea pig serum . These species-specific differences should be considered when designing experiments using mouse C9.

What are the optimal conditions for preserving C9 activity in experimental settings?

To maintain optimal C9 activity:

• Temperature control: Store purified C9 at -80°C for long-term storage. Avoid repeated freeze-thaw cycles, as these can significantly reduce activity. For working solutions, maintain C9 at 4°C and use within 24 hours .

• Buffer composition: The ideal buffer for C9 typically contains:

  • 10-20 mM HEPES or phosphate buffer (pH 7.2-7.4)

  • 140 mM NaCl

  • 0.1-0.5 mM EDTA (to chelate divalent cations that could trigger premature activation)

  • 0.02% sodium azide as a preservative for stored solutions

• Protease inhibitors: Include a protease inhibitor cocktail during purification and storage to prevent degradation.

• Activation prevention: Minimize exposure to surfaces that might trigger spontaneous activation or aggregation. Use low-protein-binding tubes and minimize air-liquid interfaces.

• Functional testing: Regularly validate C9 functionality using hemolytic assays to ensure that activity is maintained throughout storage and experimental procedures.

What are the most reliable methods for quantifying C9 concentration and activity?

Several complementary methods can be used to quantify C9:

• ELISA assays: For concentration determination, sandwich ELISA using specific anti-mouse C9 antibodies provides high sensitivity and specificity. This approach requires careful standardization with purified mouse C9 to generate accurate standard curves.

• Functional hemolytic assays: For activity assessment, antibody-sensitized erythrocyte lysis assays provide a functional readout. The rate and extent of hemolysis correlate with C9 activity. Compare samples to a standard with known activity, expressing results as hemolytic units .

• Western blotting: For detection of native and polymerized forms of C9, western blotting with specific antibodies can be used. This method can distinguish between monomeric (~70 kDa) and polymeric (high molecular weight) forms of C9.

• Spectrophotometric analysis: When measuring C9-dependent hemolysis, spectrophotometric measurement of released hemoglobin (typically at 405-415 nm) provides a quantitative readout .

• Flow cytometry: For cell-based assays, flow cytometry using fluorescently labeled antibodies against C9 or C5b-9 complexes can detect MAC formation on cell surfaces.

How should researchers design controls when working with recombinant mouse C9?

Effective controls for C9 research include:

• Positive controls:

  • Commercially available purified mouse C9 with known activity

  • Zymosan-activated mouse serum as a source of activated complement components

  • Serum from wild-type mice (for comparison with C9-deficient models)

• Negative controls:

  • Heat-inactivated serum (56°C for 30 minutes) to destroy complement activity

  • EDTA-treated samples to block complement activation

  • Serum from C9-deficient mice as a specific control for C9 activity

• Specificity controls:

  • C9-depleted serum reconstituted with purified C9

  • Anti-C9 blocking antibodies to specifically inhibit C9 function

  • Use of recombinant C9 with specific mutations in functional domains

• Technical controls:

  • Include buffer-only controls to account for spontaneous hemolysis

  • Use time-course measurements to capture kinetic differences that might be missed at single timepoints

  • Include multiple concentrations of C9 to ensure experiments are conducted within the linear range of response

How are C9-deficient mouse models generated and validated?

C9-deficient (mC9−/−) mice have been successfully generated using multiple approaches:

• TALEN-mediated targeted deletion: Transcription activator-like effector nuclease (TALEN) technology has been used to delete exon 1 of the C9 gene, which encodes the signaling peptide required for C9 secretion . The process involves:

  • Designing TALEN pairs targeting the C9 gene

  • Screening for high TALEN activity using restriction enzyme identification and sequencing

  • Injecting validated TALEN mRNA into B6 background zygotes

  • Identifying founder mice with confirmed C9 gene deletions

  • Crossing founders with wild-type mice to establish heterozygous lines

  • Intercrossing heterozygotes to generate homozygous C9-deficient mice

• Validation methods:

  • Genomic PCR and sequencing to confirm the expected deletion

  • RT-PCR and quantitative PCR to verify the absence of C9 mRNA expression

  • Western blotting to confirm the absence of C9 protein in serum

  • Functional hemolytic assays to demonstrate reduced complement-mediated lysis

What phenotypic differences have been observed between C9-deficient and wild-type mice?

C9-deficient mice exhibit several distinctive phenotypic characteristics:

How do results from C9-deficient mouse studies translate to human complement disorders?

When translating findings from C9-deficient mouse models to human conditions, several factors should be considered:

• Species differences in complement regulation: In mice, complement regulation involves duplicated genes for certain regulators like CD59, whereas humans have single copies. CD59a is the primary regulator of MAC in mice, while CD59b is mainly expressed in testis and at very low levels in bone marrow .

• Clinical correlations: Human C9 deficiency is relatively rare but has been reported in some populations (particularly in Japan). These individuals typically have increased susceptibility to Neisseria infections but are otherwise healthy, similar to observations in C9-deficient mice.

• Disease modeling: While mouse models provide valuable insights, the pathophysiology of complement-mediated diseases can differ between species. For example, the role of MAC in certain inflammatory conditions may vary between mice and humans.

• Therapeutic implications: Findings from C9-deficient mice have informed the development of anti-C9 therapies for human complement-mediated diseases. The observation that C9 deficiency attenuates but does not abolish complement function suggests that anti-C9 therapies might provide benefit without completely compromising complement defense functions.

What are the most common pitfalls in complement analysis involving C9?

Common pitfalls in complement analysis involving C9 include:

• Pre-analytical sample handling issues:

  • Inappropriate choice of anticoagulant (heparin can activate complement)

  • Prolonged storage at room temperature leading to spontaneous complement activation

  • Multiple freeze-thaw cycles causing degradation of complement proteins

  • Improper centrifugation conditions affecting protein stability

• Analytical challenges:

  • Lack of standardized assays and uniform calibrators

  • Variability between different antibodies recognizing different epitopes

  • Inconsistencies between different measurement techniques

  • Failure to include appropriate controls

• Interpretation errors:

  • Misinterpreting C9 polymerization as a proxy for complete MAC formation

  • Assuming that C9 deficiency completely abolishes MAC function

  • Overlooking species-specific differences when applying findings across different model systems

• Experimental design flaws:

  • Inappropriate time points for sample collection that miss the peak of complement activation

  • Failure to account for the temperature sensitivity of C9-mediated hemolysis

  • Inadequate statistical power to detect meaningful differences

How can researchers troubleshoot inconsistent results in C9 activity assays?

When faced with inconsistent results in C9 activity assays, researchers should:

• Standardize sample collection and processing:

  • Use consistent anticoagulants (preferably EDTA for activation studies)

  • Process samples within one hour of collection

  • Maintain consistent temperature conditions (4°C for processing)

  • Aliquot samples to avoid freeze-thaw cycles

• Validate reagents and controls:

  • Use fresh, validated antibodies with confirmed specificity

  • Include positive and negative controls in each experiment

  • Perform titration experiments to ensure working within the linear range

  • Consider using commercial standards for calibration

• Optimize assay conditions:

  • Control temperature precisely during all assay steps

  • Validate incubation times to capture optimal kinetics

  • Ensure consistent pH and ionic strength of buffers

  • Minimize variation in cell concentrations for hemolytic assays

• Cross-validate with multiple methods:

  • Confirm functional hemolytic assay results with immunological detection methods

  • Use both quantitative (ELISA) and qualitative (Western blot) approaches

  • Consider using flow cytometry to assess MAC deposition on cell surfaces

• Data analysis considerations:

  • Apply appropriate statistical methods that account for the variability inherent in biological samples

  • Consider normalizing data to internal controls

  • Examine dose-response relationships rather than single-concentration experiments

What are the key differences between various expression systems for producing recombinant mouse C9?

Different expression systems offer distinct advantages and limitations for producing recombinant mouse C9:

• Mammalian expression systems (e.g., CHO, HEK293 cells):

  • Advantages: Proper post-translational modifications; natural signal peptide processing; correct folding; high biological activity

  • Disadvantages: Lower yields; higher cost; more complex purification; longer production times

  • Optimal for: Functional studies requiring fully active C9; structural studies requiring native conformation

• Insect cell expression systems (e.g., Sf9, High Five cells):

  • Advantages: Higher yields than mammalian systems; some post-translational modifications; relatively efficient folding

  • Disadvantages: Differences in glycosylation patterns; potentially altered activity

  • Optimal for: Structural studies; antibody production; applications where glycosylation is less critical

• Bacterial expression systems (e.g., E. coli):

  • Advantages: Highest yields; simplest and most cost-effective; rapid production

  • Disadvantages: Lack of post-translational modifications; potential folding issues; often requires refolding; formation of inclusion bodies

  • Optimal for: Antigen preparation; studies of specific domains that don't require full functionality

• Cell-free expression systems:

  • Advantages: Rapid production; avoids cellular toxicity issues; allows incorporation of non-natural amino acids

  • Disadvantages: Lower yields; higher cost; limited post-translational modifications

  • Optimal for: Pilot studies; production of toxic proteins; structure-function relationship studies